Estabrook Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Estabrook Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11K	Buy	22 +8	+57%	+$3.84K	﹤0.01%	282
2026 Q1	$6.88K	Hold	14	–	–	﹤0.01%	301
2025 Q4	$8.11K	Hold	14	–	–	﹤0.01%	279
2025 Q3	$6.79K	Sell	14 -2	-13%	-$931	﹤0.01%	286
2025 Q2	$6.49K	Buy	16 +2	+14%	+$836	﹤0.01%	286
2025 Q1	$6.97K	Buy	14 +2	+17%	+$1.08K	﹤0.01%	273
2024 Q4	$6.24K	Hold	12	–	–	﹤0.01%	291
2024 Q3	$7.42K	Hold	12	–	–	﹤0.01%	294
2024 Q2	$6.64K	Buy	12 +1	+9%	+$573	﹤0.01%	292
2024 Q1	$6.39K	Buy	11 +1	+10%	+$561	﹤0.01%	298
2023 Q4	$5.31K	Hold	10	–	–	﹤0.01%	309
2023 Q3	$5.06K	Hold	10	–	–	﹤0.01%	312
2023 Q2	$5.22K	Hold	10	–	–	﹤0.01%	320
2023 Q1	$5.76K	Hold	10	–	–	﹤0.01%	327
2022 Q4	$5.51K	Hold	10	–	–	﹤0.01%	334
2022 Q3	$5.07K	Hold	10	–	–	﹤0.01%	331
2022 Q2	$5.43K	Hold	10	–	–	﹤0.01%	350
2022 Q1	$5.91K	Hold	10	–	–	﹤0.01%	346
2021 Q4	$6.67K	Hold	10	–	–	﹤0.01%	355
2021 Q3	$5.71K	Hold	10	–	–	﹤0.01%	286
2021 Q2	$5.04K	Buy	+10	New	+$4.72K	﹤0.01%	288
2013 Q4	–	Sell	-100	Closed	-$9.21K	–	480
2013 Q3	$9.21K	Hold	100	–	–	﹤0.01%	392
2013 Q2	$8.46K	Buy	+100	New	+$8.32K	﹤0.01%	398

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Estabrook Capital Management's TMO Position: Q2 2026 in Review

Estabrook Capital Management increased its Thermo Fisher Scientific (TMO) stake by 57% in Q2 2026, buying an estimated $3.84K and bringing the position to 22 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #282.

Estabrook Capital Management first reported a position in TMO in Q2 2013 and has held it in 23 quarters since. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Estabrook Capital Management held 22 shares of Thermo Fisher Scientific worth $11K as of Q2 2026.
Estabrook Capital Management bought 8 Thermo Fisher Scientific shares in Q2 2026, an estimated $3.84K.
Thermo Fisher Scientific made up ﹤0.01% of Estabrook Capital Management's portfolio in Q2 2026, its #282 holding.
Estabrook Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 23 quarters since.
2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Estabrook Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.